News & Updates

The novel, small-molecule, orally administered third-generation BCR-ABL1 tyrosine kinase inhibitor (TKI) olverembatinib is well-tolerated and shows promising antitumour activity in patients with heavily pretreated chronic-phase chronic myeloid leukaemia (CML), according to the results of a phase 1B study.

Transplantation of maternal faecal microbiota may safely correct gut microbiota imbalance in infants born via caesarean section (C-section), according to the results of the SECFLOR* trial.

Nonmodifiable factors such as male sex, type of SCN5A mutation, and polygenic risk score are independently associated with outcomes in patients with Brugada syndrome (BrS), a study has shown

Pooled saliva tests for congenital cytomegalovirus (cCMV) infection are both accurate and cost-efficient, potentially transforming the implementation of universal cCMV screening, suggests a study presented at IDWeek 2024.

A single injection of mRNA-1403, a multivalent norovirus mRNA vaccine, induces a robust serum histo-blood group antigen (HBGA)-blocking antibody response across all dose levels in adults, as shown by interim results of an ongoing phase I/II trial presented at IDWeek 2024. Comparable findings have been observed with serum virus-like particle (VLP)-binding antibody responses.